Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Investigation|July 28, 2022
SPTLC1 variants associated with ALS produce distinct sphingolipid signatures through impaired interaction with ORMDL proteinsMuseer A Lone, Mari J Aaltonen, Aliza Zidell, et al.
Elife|February 26, 2020
An alternatively spliced, non-signaling insulin receptor modulates insulin sensitivity via insulin peptide sequestration in C. elegansBryan A Martinez, Pedro Reis Rodrigues, Ricardo M Nuñez Medina, et al.
Antimicrobial Agents and Chemotherapy|November 6, 2013
The natural diyne-furan fatty acid EV-086 is an inhibitor of fungal delta-9 fatty acid desaturation with efficacy in a model of skin dermatophytosisPhilipp Knechtle, Melanie Diefenbacher, Katrine B V Greve, et al.
Brain : a Journal of Neurology|October 22, 2025
Antisense oligonucleotides reverse SPTLC1-related hereditary sensory neuropathy in a mouse modelJinhong Meng, Shunyi Ma, Museer A Lone, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 2, 2023
Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosisMaike F Dohrn, Danique Beijer, Museer A Lone, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 2, 2023
Recurrent de novo SPTLC2 variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesisSafoora B Syeda, Museer A Lone, Payam Mohassel, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2026
The COPI coatomer influences LDL receptor activity, hepatic lipid storage, and apoB secretionGrigorios Panteloglou, Jérôme Robert, Marieke Smit, et al.
Nature Medicine|June 1, 2021
Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesisPayam Mohassel, Sandra Donkervoort, Museer A Lone, et al.
Pageof 4